Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: arterys.com
Global Number of Employees (Latest): 40
Year Founded: 2007
Total Amount Raised (CAD mm)†: 97.69
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) 18.00
Latest Pre-Money Valuation ($ mm) 5.00
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Arterys Inc. develops a software-as-a-Service (SaaS) based analytics platform to transform medical imaging diagnostics for improving the lives of patients and clinicians. Its solutions include Cardio AI, an artificial intelligence assistant for cardiac magnetic resonance image analysis; Lung AI, a solution for lung image analysis; Liver Ai, an AI assistant for liver image analysis; and Chest/MSK AI, a solution that automatically detects fracture, dislocation, elbow joint effusion, pleural effusion, pulmonary nodule, pulmonary opacity, and pneumothorax. The company also offers Arterys PHI Service, a service that enables physicians to access patient data from anywhere. Its platform is used by radiologists for applications in clinical indications to visualize and quantify blood flow in the human body. The company was formerly known as Morpheus Medical, Inc. and changed its name to Arterys Inc. in April 2013. Arterys Inc. was founded in 2007 and is based in San Francisco, California with additional offices in Calgary, Canada and Paris, France. As of October 5, 2022, Arterys Inc. operates as a subsidiary of Tempus Labs, Inc..


Financial Information (Currency: CAD, in mm)
Total Revenue
 7.1
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
 40
Net Debt
-
U.S. Number of Employees 2021
 20
U.S. Number of Employees 2020
 13
U.S. Last Year Employee Growth %
 53.8
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Beckers, Fabien 
Co-Founder, CEO & Director
Axerio-Cilies, John 
Co-Founder, CTO, Secretary & Director
Hsiao, Albert 
Co-Founder
Vasanawala, Shreyas 
Co-Founder
Henn, Timothy G.
Chief Financial Officer
Cholowsky, Sharon 
Director of Regulatory & Compliance
McCaffrey, Cia 
Vice President of Talent and Culture

Key Board Members
Name
Title
Beckers, Fabien 
Co-Founder, CEO & Director
Axerio-Cilies, John 
Co-Founder, CTO, Secretary & Director


Primary Industry Classification
Health Care Technology


Primary Office Location
51 Federal Street | San Francisco, CA | 94107 | United States
Phone: 650 319 7230   

Parent Company
Tempus Labs, Inc.

Prior Investors
AME Cloud Ventures, LLC (Chih-Yuan Yang), Asset Management Ventures (David Fleshman), Benslie investment group, DNA Capital Consultoria Ltda., Emergent Medical Partners, GE Ventures, LLC, Medical Technologies Innovators, Inc., Morado Venture Partners, New York-Presbyterian Fund, Inc., Northwell Ventures, Norwich Ventures, ORI Capital, Revelation Capital Management, LLC, Revelation Partners, LLC, StartX, StartX Fund, Temasek Holdings (Private) Limited, Texas Medical Center Accelerator, Varian Medical Systems, Inc.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-05-2022
Oct-05-2022
Merger/Acquisition
Target
Arterys Inc.
Tempus Labs, Inc.
Asset Management Ventures,Emergent Medical Partners,Norwich Ventures,AME Cloud Ventures, LLC,Morado Venture Partners,GE Ventures, LLC,StartX,Temasek Holdings (Private) Limited,Northwell Ventures,ORI Capital,Texas Medical Center Accelerator,DNA Capital Consultoria Ltda.,Revelation Partners, LLC,Revelation Capital Management, LLC,Medical Technologies Innovators, Inc.
-
Apr-27-2020
May-29-2020
Private Placement
Target
Arterys Inc.
Emergent Medical Partners,Temasek Holdings (Private) Limited,Varian Medical Systems, Inc.,Benslie investment group,Revelation Partners, LLC

28.00
Nov-03-2017
Nov-15-2017
Private Placement
Target
Arterys Inc.
Emergent Medical Partners,GE Ventures, LLC,Temasek Holdings (Private) Limited,Northwell Ventures,New York-Presbyterian Fund, Inc.,Varian Medical Systems, Inc.,ORI Capital,DNA Capital Consultoria Ltda.

30.06
Nov-09-2015
-
Private Placement
Target
Arterys Inc.
Asset Management Ventures,Emergent Medical Partners,Norwich Ventures,AME Cloud Ventures, LLC,Morado Venture Partners,GE Ventures, LLC,StartX Buyer Funds:StartX Fund

12.70
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Nov-15-2022
Client Announcements
Arterys Wins Artificial Intelligence Solutions for Healthcare Agreement with Premier, Inc
Oct-05-2022
M&A Transaction Closings
Tempus Labs, Inc. acquired Arterys Inc.
Apr-07-2022
Product-Related Announcements
Arterys Announces Several New Modules to Its Already Robust Cardio AI Clinical Application and an Additional FDA AI Clearance Based on Deep Learning
Nov-30-2021
Client Announcements
Arterys Signs Global Distribution Agreement with iCAD, Inc. to Launch Its New Breast AI SaaS Solution
Nov-29-2021
Client Announcements
Arterys Announces its Partnership with Cercare Medical to Make Their AI-Powered Imaging Solution, Cercare Perfusion, Available on Arterys Platform


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 06:59 PM
Arterys Inc.
Arterys Inc
Reports
54
GlobalData

Aug 23, 2023 06:33 AM
Arterys Inc.
Arterys Inc - Medical Equipment - Deals and Alliances Profile
Reports
28
GlobalData

Jun 19, 2023 05:36 AM
Arterys Inc.
Arterys Inc
Reports
54
GlobalData

May 09, 2023 03:57 AM
Arterys Inc.
Arterys Inc - Medical Equipment - Deals and Alliances Profile
Reports
28
GlobalData

Mar 17, 2023 02:58 AM
Arterys Inc.
Arterys Inc
Reports
54
GlobalData

Jan 23, 2023 05:00 AM
Arterys Inc.
Arterys Inc - Medical Equipment - Deals and Alliances Profile
Reports
28
GlobalData

Dec 14, 2022 11:13 PM
Arterys Inc.
Arterys Inc
Reports
56
GlobalData

Oct 27, 2022 07:31 AM
Arterys Inc.
Arterys Inc - Medical Equipment - Deals and Alliances Profile
Reports
29
GlobalData

Sep 23, 2022 04:30 AM
Arterys Inc.
Arterys Inc
Reports
61
GlobalData

Jul 20, 2022 04:50 AM
Arterys Inc.
Arterys Inc - Medical Equipment - Deals and Alliances Profile
Reports
29


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Arterys Cardio DLTM

Key Board Members Details
Name
Title
Phone
Fax
Email
Beckers, Fabien 
Co-Founder, CEO & Director
-
-

Axerio-Cilies, John 
Co-Founder, CTO, Secretary & Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Beckers, Fabien 
Co-Founder, CEO & Director
-
-

Axerio-Cilies, John 
Co-Founder, CTO, Secretary & Director
-
-

Hsiao, Albert 
Co-Founder
650 319 7230
-

Vasanawala, Shreyas 
Co-Founder
650 319 7230
-

Henn, Timothy G.
Chief Financial Officer
650 319 7230
-

Cholowsky, Sharon 
Director of Regulatory & Compliance
650 319 7230
-

McCaffrey, Cia 
Vice President of Talent and Culture
650 319 7230
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
